Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("Acurx" or the "Company"), a late-stage biopharmaceutical company developing a new class of small molecule antibiotics for difficult-to-treat bacterial ...
Announcing a new article publication for Zoonoses journal. The prevalence of antimicrobial resistance is increasing among gram-positive bacteria, particularly the resistance of methicillin-resistant ...
In a recent study, researchers demonstrated that a novel compound could treat flesh-eating Gram-positive bacterial infections in mice, potentially offering a new class of antibiotics. Researchers at ...
Chemists from the University of Warwick and Monash University have discovered a promising new antibiotic that shows activity against drug-resistant bacterial pathogens, including MRSA and VRE ...
Researchers at Washington University School of Medicine in St. Louis developed a novel compound that effectively clears Gram-positive bacterial infections in mice, in particular skin and soft tissue ...
Animal tests show promise to target invasive strain of E. coli but approval for use in humans is still years away ...
Half of the Staphylococcus epidermidis isolates found in raw milk from dairy cattle and sheep were multidrug resistant.
News-Medical.Net on MSN
Five-year project seeks new weapons against drug-resistant bacteria
Lethal lettuce in Missouri. Murderous onions in Colorado. To biochemists at the University of Oklahoma, these aren't just ...
Symptoms and Patient-Reported Well-Being: Do They Predict Survival in Malignant Pleural Mesothelioma? A Prognostic Factor Analysis of EORTC-NCIC 08983: Randomized Phase III Study of Cisplatin With or ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback